Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

Roy S. Herbst, Edward B. Garon, Dong Wan Kim, Byoung Chul Cho, Jose L. Perez-Gracia, Ji Youn Han, Catherine Dubos Arvis, Margarita Majem, Martin D. Forster, Isabelle Monnet, Silvia Novello, Zsuzsanna Szalai, Matthew A. Gubens, Wu Chou Su, Giovanni Luca Ceresoli, Ayman Samkari, Erin H. Jensen, Gregory M. Lubiniecki, Paul Baas

研究成果: Article

3 引文 斯高帕斯(Scopus)

摘要

PURPOSE: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing advanced non‒small-cell lung cancer (NSCLC) in patients with a tumor proportion score (TPS) ≥ 50% and ≥ 1%. We report KEYNOTE-010 long-term outcomes, including after 35 cycles/2 years or second-course pembrolizumab. METHODS: Of 1,033 patients randomly assigned (intention to treat), 690 received up to 35 cycles/2 years of pembrolizumab 2 mg/kg (n = 344) or 10 mg/kg (n = 346) every 3 weeks, and 343 received docetaxel 75 mg/m2 every 3 weeks. Eligible patients with disease progression after 35 cycles/2 years of pembrolizumab could receive second-course treatment (up to 17 cycles). Pembrolizumab doses were pooled because no between-dose difference was observed at primary analysis. RESULTS: Pembrolizumab continued to improve OS over docetaxel in the PD-L1 TPS ≥ 50% and ≥ 1% groups (hazard ratio [HR], 0.53; 95% CI, 0.42 to 0.66; P < .00001; and HR, 0.69; 95% CI, 0.60 to 0.80; P < .00001, respectively) after a 42.6-month (range, 35.2-53.2 months) median follow-up. Estimated 36-month OS rates were 34.5% versus 12.7% and 22.9% versus 11.0%, respectively. Grade 3-5 treatment-related adverse events occurred in 16% versus 37% of patients, respectively. Seventy-nine of 690 patients completed 35 cycles/2 years of pembrolizumab; 12-month OS and progression-free survival rates after completing treatment were 98.7% (95% CI, 91.1% to 99.8%) and 72.5% (95% CI, 59.9% to 81.8%), respectively. Seventy-five patients (95%) had objective response (RECIST v1.1, blinded independent central review) and 48 (64%) had ongoing response. Grade 3-5 treatment-related adverse events occurred in 17.7% of patients. Fourteen patients received second-course pembrolizumab: 5 completed 17 cycles, 6 (43%) had partial response, and 5 (36%) had stable disease. CONCLUSION: Pembrolizumab provided long-term OS benefit over docetaxel, with manageable safety, durable responses among patients receiving 2 years of treatment, and disease control with second-course treatment, further supporting pembrolizumab for previously treated, PD-L1‒expressing advanced NSCLC.

原文English
頁(從 - 到)1580-1590
頁數11
期刊Journal of clinical oncology : official journal of the American Society of Clinical Oncology
38
發行號14
DOIs
出版狀態Published - 2020 五月 10

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

指紋 深入研究「Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study」主題。共同形成了獨特的指紋。

  • 引用此

    Herbst, R. S., Garon, E. B., Kim, D. W., Cho, B. C., Perez-Gracia, J. L., Han, J. Y., Arvis, C. D., Majem, M., Forster, M. D., Monnet, I., Novello, S., Szalai, Z., Gubens, M. A., Su, W. C., Ceresoli, G. L., Samkari, A., Jensen, E. H., Lubiniecki, G. M., & Baas, P. (2020). Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(14), 1580-1590. https://doi.org/10.1200/JCO.19.02446